Antibodies specific for epidermal growth factor receptor variant iii and their uses
AssigneePfizer Inc.
InventorsOi Kwan WONG, Joyce Ching CHOU, Barbra Johnson SASU
Life of this patent
Estimating the term…
Abstract
The present invention provides antibodies that specifically bind to EGFRvIII (Epidermal Growth Factor Receptor Variant III). The invention further provides bispecific antibodies that bind to EGFRvIII and another antigen (e.g., CD3) as well as antibody conjugates (e.g., antibody-drug-conjugates). The invention further relates to antibody encoding nucleic acids, and methods of obtaining such antibodies (monospecific and bispecific) and antibody conjugates. The invention further relates to therapeutic methods for use of these antibodies and antibody conjugates for the treatment of EGFRvIII-mediated pathologies, including cancer such as glioblastoma.
Claims23
An isolated antibody, which specifically binds to Epidermal Growth Factor Receptor Variant III (EGFRvIII), wherein the antibody comprises
- a) heavy chain variable (VH) region comprising a sequence selected from SEQ ID NOs:
- 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 25, 30, 32, 34, and 35;
- and
- b) a light chain variable (VL) region comprising a sequence selected from SEQ ID NOs:
- 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 29, 31, 33, 31, and 36.
An isolated antibody which specifically binds to Epidermal Growth Factor Receptor Variant III (EGFRvIII), wherein the antibody comprises:
- a) a heavy chain variable (VH) region comprising a sequence selected from SEQ ID NOs:
- 37, 39, 41, 43, 44, and 46;
- and
- b) a light chain variable (VL) region comprising a sequence selected from SEQ ID NOs:
- 38, 40, 42, 40, 45, and 47.
3-9. (canceled)
15-16. (canceled)
Dependencies are inferred from the claim text.